Clinical effectiveness of TASIGNA® in imatinib-resistant or -intolerant Ph+ CML-CP was based on the unconfirmed major cytogenetic and complete hematologic response rates. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.